Hedi Brahim - Transgene CEO Director

TRGNF Stock  USD 1.59  0.00  0.00%   

Insider

Hedi Brahim is CEO Director of Transgene SA
Age 42
Phone33 3 88 27 91 00
Webhttps://www.transgene.fr

Transgene Management Efficiency

The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Troy WeaverAxalta Coating Systems
52
Tyrone JordanAxalta Coating Systems
59
Gregory JaneyToro Co
42
Alisa MallJBG SMITH Properties
43
Joseph PierceMerit Medical Systems
N/A
Kevin CarpenterToro Co
49
John KnorppMerit Medical Systems
N/A
Stephen WebsterLuxfer Holdings PLC
52
Barbat RodgersJBG SMITH Properties
N/A
Andrew WamserMativ Holdings
50
Gina BoswellAcco Brands
58
Omar HoekMativ Holdings
55
Sarma MalladiMativ Holdings
N/A
Jill PembertonToro Co
50
Laura MurrayHudson Pacific Properties
N/A
Michel VoigtMerit Medical Systems
51
Nicole PriestMerit Medical Systems
N/A
Missy ElamMativ Holdings
N/A
E RajkowskiAcco Brands
62
George XandersJBG SMITH Properties
38
Michael GaidenLuxfer Holdings PLC
N/A
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people. Transgene SA [TRGNF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Transgene SA Leadership Team

Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Maud MD, VP Officer
Eric Quemeneur, Executive Vice President Vice President - Research & Development, Member of the Management Committee
Gaelle Stadtler, VP HR
JeanPhilippe Del, Vice President - Finance, Member of the Management Committee
Elisabetta Castelli, Director of Investor Relations
Hedi Brahim, CEO Director
Lucie Larguier, Director IR
Steven RPh, VP Officer
LLM JD, Gen VP
Philippe Slos, Head Laboratory

Transgene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Transgene Pink Sheet

Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.